Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases
Many patients with systemic autoimmune rheumatic diseases (SARDs) require
immunosuppression to reduce disease activity, but this also has important possible …
immunosuppression to reduce disease activity, but this also has important possible …
Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
RH Haberman, S Um, JE Axelrad, RB Blank… - The Lancet …, 2022 - thelancet.com
Studies have revealed that patients with immunemediated inflammatory diseases, especially
those on immunomodulatory medication, have attenuated immunogenicity to COVID-19 …
those on immunomodulatory medication, have attenuated immunogenicity to COVID-19 …
Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and …
V Furer, T Eviatar, T Freund, H Peleg… - Annals of the …, 2022 - ard.bmj.com
Objectives To evaluate long-term kinetics of the BNT162b2 mRNA vaccine-induced immune
response in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and …
response in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and …
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a …
Background The durability of vaccine-induced humoral immunity against SARS-CoV-2 in
patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive …
patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive …
Susceptibility to COVID-19 and immunologic response to vaccination in patients with immune-mediated inflammatory diseases
Immune-mediated inflammatory diseases (IMIDs) are a highly heterogeneous group of
diseases that share a common etiology of immune dysregulation, such as rheumatoid …
diseases that share a common etiology of immune dysregulation, such as rheumatoid …
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine …
J Serwanga, C Baine, S Mugaba, V Ankunda… - Frontiers in …, 2023 - frontiersin.org
Introduction The duration and timing of immunity conferred by COVID-19 vaccination in sub-
Saharan Africa are crucial for guiding pandemic policy interventions, but systematic data for …
Saharan Africa are crucial for guiding pandemic policy interventions, but systematic data for …
Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
J Wroński, B Jaszczyk, L Roszkowski… - Frontiers in …, 2022 - frontiersin.org
Introduction Previous studies have shown a reduction in the effectiveness of primary COVID-
19 vaccination in patients with rheumatic diseases. However, limited data is available …
19 vaccination in patients with rheumatic diseases. However, limited data is available …
[HTML][HTML] Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases
D Mrak, F Kartnig, D Sieghart, E Simader… - Journal of …, 2023 - Elsevier
Background A 3 rd COVID-19 vaccination is currently recommended for patients under
immunosuppression. However, a fast decline of antibodies against the SARS-CoV-2 …
immunosuppression. However, a fast decline of antibodies against the SARS-CoV-2 …
Safety and immunogenicity following the second and third doses of the BNT162b2 mRNA COVID-19 vaccine in adolescents with juvenile-onset autoimmune …
M Heshin-Bekenstein, A Ziv, N Toplak, S Lazauskas… - Vaccines, 2023 - mdpi.com
Background: To explore the long-term safety and dynamics of the immune response induced
by the second and third doses of the BNT162b2 mRNA COVID-19 vaccine in adolescents …
by the second and third doses of the BNT162b2 mRNA COVID-19 vaccine in adolescents …
Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review
Purpose: There is a paucity of evidence on the impact of immune-mediated inflammatory
disease (IMID) treatments on the immunogenicity of SARS-CoV-2 vaccination. The purpose …
disease (IMID) treatments on the immunogenicity of SARS-CoV-2 vaccination. The purpose …